Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of-concept data for this asset could lead to substantial upside, the analyst tells investors in a research note. The firm also believes significant value can be unlocked for ATI-045 in asthma and other large respiratory indications after upcoming China Phase 2 data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Aclaris Therapeutics initiated with an Outperform at Scotiabank
- Aclaris Therapeutics: Strong Pipeline and Financial Stability Justify Buy Rating
- Aclaris Therapeutics Reports 2024 Financial Results
- Aclaris Therapeutics files $300M mixed securities shelf